PAKISTAN JOURNAL OF MEDICAL SCIENCES, cilt.32, sa.2, ss.309-313, 2016 (SCI-Expanded)
Objective: Neutropenia is a serious adverse event that necessitates dosage reduction in patients receiving chemotherapy. In this study, we evaluated the oxidative stress and antioxidant parameters in neutropenic patients after chemotherapy both during the neutropenic period and after successful treatment of neutropenia with filgrastim.